Here’s a bombshell that could reshape the future of flu vaccines: the FDA has refused to even review Moderna’s application for its groundbreaking mRNA flu vaccine, leaving the company—and the scientific community—scratching their heads. But here’s where it gets controversial: Was this decision based on legitimate scientific concerns, or is it part of a broader political pushback against mRNA technology? Let’s dive in.
The U.S. Food and Drug Administration (FDA) has declined to accept Moderna’s application to review its first mRNA-based seasonal flu vaccine, the company announced on Tuesday. This marks yet another setback for mRNA technology, which has faced increasing scrutiny from certain health officials within the Trump administration. According to Moderna, the FDA’s refusal was rooted in the claim that the clinical trial lacked an ‘adequate and well-controlled’ design, specifically because the control arm didn’t align with the ‘best-available standard of care’ in the U.S. at the time of the study. This feedback came in a letter dated February 3, which Moderna made public. Interestingly, the agency didn’t raise any concerns about the vaccine’s safety or efficacy.
Moderna’s president, Dr. Stephen Hoge, expressed shock at the decision, telling CNN, ‘At no point did anybody say that our trial design was inadequate.’ The company has requested a meeting with FDA officials to clarify the path forward. Meanwhile, the U.S. Department of Health and Human Services (HHS) remained tight-lipped, stating that the FDA typically doesn’t comment on communications with individual sponsors.
And this is the part most people miss: Moderna’s clinical trial, involving 40,700 participants, used Fluarix—a standard-dose seasonal flu vaccine—as a comparator to demonstrate the mRNA vaccine’s safety and efficacy. The company claims the FDA approved this plan in April 2024 and even suggested including data comparing their vaccine to a high-dose flu vaccine for individuals over 65, which Moderna did. As recently as August, the FDA reportedly indicated it would review the application and address any comparator issues during the process. Yet, last week, the agency abruptly refused to review the application altogether. The decision was signed by Dr. Vinay Prasad, a known critic of the government’s COVID-19 response, who now heads the FDA’s Center for Biologics Evaluation and Research.
Here’s where it gets even more intriguing: Prasad previously claimed, without evidence, that COVID-19 vaccines caused the deaths of 10 children. His appointment under HHS Secretary Robert F. Kennedy Jr. has raised eyebrows, especially as the Trump administration has increasingly distanced itself from mRNA technology. In August, HHS canceled $500 million in mRNA vaccine development projects, controversially asserting that these vaccines ‘fail to protect effectively’ against respiratory infections like COVID and flu—a claim that contradicts widespread scientific evidence.
But let’s pause for a moment: Isn’t it ironic that mRNA technology, hailed as a triumph during the pandemic for its role in developing COVID-19 vaccines at record speed, is now being sidelined? COVID-19 vaccines alone are estimated to have saved millions of lives. The potential of mRNA flu vaccines is enormous—they could offer better protection, be tailored to specific geographic strains, and even be combined with COVID-19 vaccines for dual protection in a single shot. Moderna’s Phase 3 study showed its mRNA flu shot was 27% more effective than Fluarix in adults over 50, and another trial demonstrated superiority over high-dose vaccines in those over 65.
The real game-changer? mRNA vaccines can be developed much faster than traditional ones. While current flu vaccines are designed in February for the following fall, mRNA vaccines could be tailored closer to flu season, potentially better matching circulating strains. As Dr. Hoge noted, ‘Better matching usually equals better protection.’
Despite the FDA’s refusal, Moderna’s combination flu and COVID-19 mRNA vaccine is moving forward in other countries, with the first approval expected in Europe this year. But here’s the burning question: Is the FDA’s decision a legitimate scientific critique, or is it influenced by political agendas? And what does this mean for the future of mRNA technology in the U.S.? Share your thoughts in the comments—this is a conversation that needs to happen.
